 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumabTM, today announced that the Companys management team will present and host meetings with investors at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021, the Roth Conference being held from March 15-17, 2021, and t 